POS1046 IMPROVEMENTS IN PATIENT-REPORTED IMPACT OF PSORIATIC ARTHRITIS WITH IL-12/23 (USTEKINUMAB) OR TUMOUR NECROSIS FACTOR INHIBITORS: 1-YEAR DATA FROM THE LARGE, REAL-WORLD PsABIO STUDY

Background: Psoriatic arthritis (PsA) negatively impacts patients’ (pts) quality of life (QoL), with a high burden of pain, fatigue and psychological distress. The 12-item Psoriatic Arthritis Impact of Disease questionnaire (PsAID-12) is a validated measure of pt-reported disease impact. Objectives: To analyse PsAID-12 score changes in the overall population and specific subgroups of interest, and assess correlation of these changes using Health Assessment Questionnaire Disability Index (HAQ-DI). Methods: PsABio (NCT02627768) is a multinational, prospective, observational study in pts with PsA receiving ustekinumab (UST) or a tumour necrosis factor inhibitor (TNFi) as a 1st/2nd/3rd-line biologic. Descriptive statistics, including 95% CI, are presented at baseline (BL) and 1 year. Linear regression, including propensity score (PS) adjustment for BL covariates, was used to compare change in PsAID-12 total from BL to 1 year between treatments. The relationship between changes in PsAID-12 and HAQ-DI was investigated using Spearman’s correlation. Results: Data were available for 438 UST and 455 TNFi pts. From BL to 1 year, significant improvements were seen in total PsAID-12 scores and in all domains with both treatments (Figure 1). PS-adjusted treatment comparison showed no difference in total PsAID-12 improvement (regression coefficient [95% CI]: 0.14 [-0.22; 0.51], p=0.4433), or in any domain, except skin problems, which improved significantly more with UST than TNFi (-0.55 [-1.04, -0.06], p=0.0277). Improvements in PsAID-12 and HAQ-DI showed strong positive correlation with both treatments (UST: r=0.63, p Conclusion: Treatment with IL-12/23 (UST) or TNF inhibitors significantly improved pt-reported disease impact at 1 year. PS-adjusted PsAID-12 improvements did not differ significantly between treatments, except skin problems (better with UST). Improvements in disease impact and physical functioning (HAQ-DI) were strongly correlated, emphasising the effect of these biologics on QoL in PsA pts. Acknowledgements: This study was funded by Janssen. Disclosure of Interests: Laure Gossec Consultant of: AbbVie, Amgen, Bioepis, Biogen, Bristol-Myers Squibb, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung, Sanofi-Aventis, UCB, Grant/research support from: Amgen, Galapagos, Janssen, Lilly, Pfizer, Sandoz, Sanofi, Stefan Siebert Speakers bureau: AbbVie, Amgen (previously Celgene), Biogen, Janssen, Novartis, UCB, Consultant of: AbbVie, Janssen, UCB, Grant/research support from: Amgen (previously Celgene), Boehringer Ingelheim, Bristol-Myers Squibb, GSK, Janssen, Novartis, Pfizer, UCB, Paul Bergmans Shareholder of: Johnson & Johnson, Employee of: Janssen, Kurt de Vlam Speakers bureau: AbbVie, Amgen, Eli Lilly, Novartis, UCB, Paid instructor for: Amgen, Galapagos, UCB, Consultant of: Eli Lilly, Galapagos, Johnson & Johnson, Novartis, UCB, Grant/research support from: Celgene, Elisa Gremese: None declared, Beatriz Joven-Ibanez Speakers bureau: AbbVie, Celgene, Janssen, MSD, Novartis, Pfizer, Tatiana Korotaeva Speakers bureau: AbbVie, Amgen, Biocad, Lilly, Janssen, MSD, Novartis, Novartis-Pfizer, Sandoz, UCB, Consultant of: AbbVie, Amgen, Biocad, Lilly, Janssen, MSD, Novartis, Novartis-Sandoz, Pfizer, UCB, Grant/research support from: Pfizer, Wim Noel Employee of: Janssen, Michael Nurmohamed Speakers bureau: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Menarini, MSD, Mundipharma, Pfizer, Roche, Sanofi, UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Janssen, Menarini, MSD, Mundipharma, Pfizer, Roche, Sanofi, UCB, Grant/research support from: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Menarini, MSD, Mundipharma, Pfizer, Roche, Sanofi, UCB, Petros Sfikakis Consultant of: AbbVie, Actelion, Boehringer Ingelheim, Enorasis, Farmaserv-Lilly, Genesis, Gilead, Pfizer, MSD, Novartis, UCB, Grant/research support from: AbbVie, Amgen, Boehringer Ingelheim, Faran, Janssen, Pfizer, Roche, Elke Theander Employee of: Janssen, Josef S. Smolen Speakers bureau: AbbVie, Amgen, AstraZeneca, Astro, Bristol-Myers Squibb, Celgene, Celltrion, Chugai, Gilead, ILTOO, Janssen, Lilly, MSD, Novartis- Sandoz, Pfizer, Roche, Samsung, Sanofi, UCB, Grant/research support from: AbbVie, AstraZeneca, Lilly, Novartis, Roche.